Kronos Bio Inc at Jefferies Healthcare Conference Transcript
Thank you. Good morning, everyone, and welcome to another session here at the Jefferies Healthcare Conference. I am very pleased to have the team from Kronos Bio up here with us.
Kronos, obviously, has been embarking on a unique oncology platform with their novel CDK9 inhibitor. I would love to maybe just open it up to Norbert to make some brief comments about the status of the pipeline, specifically with the CDK9 inhibitor, as well as some of the developments, obviously, with AML, two different stories there, and talk a little bit about each one of those and the value proposition. And then we'll go into some questions.
Thanks, Mike. And I would like to thank you and Jefferies for inviting us. And as I said, Mike, it's nice to see you in person rather than on TV. So that's great.
Now, we are making a lot of progress. I'm very excited about what we have. We really have three pillars, so to speak, two clinical stage programs, a CDK9 inhibitor and a SYK inhibitor, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |